Pure Global
NCT00523588

Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser

Single Blind, Controlled, Single-Center Study of Laser Treatment in Cutaneous Lupus Erythematosus
University of Pennsylvania·Phase 2·ClinicalTrials.gov·procedureCompleted
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Cutaneous Lupus Erythematosus
Drug/Device/Intervention
laser treatment (Candela Vbeam Perfecta™)
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
University of Pennsylvania
Location
Philadelphia, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2007
End date
Jan 01, 2010
Enrollment
10 participants
Primary outcome

Comparison of laser treated CLE skin lesions with a non-treated control CLE lesion of the same patient evaluated by the CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index) and the M-CLASI (Modified CLASI).

Summary

The purpose of using the 595 nm Vbeam Perfecta™ flashlamp-excited, pulsed dye laser in this
 study is to help improve study patients' skin disease. Cutaneous lupus erythematosus (CLE)
 often presents with disfiguring vascular lesions which are frequently difficult to treat with
 the available therapeutic measures, such as photoprotection, topical steroids, and
 antimalarials. Laser therapy provides an alternative treatment option for CLE patients.
 Although there has been documented experience with laser treatment in CLE patients, no study
 comparing treated lesions to the natural course of the disease has been conducted.

ICD-10 classifications
Subacute cutaneous lupus erythematosusLupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosusSystemic lupus erythematosus, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT00523588
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT00523588 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Pennsylvania and is currently Completed. The study focuses on Cutaneous Lupus Erythematosus. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.